FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2174456430> ?p ?o ?g. }

• W2174456430 endingPage "557" @default.
• W2174456430 startingPage "548" @default.
• W2174456430 abstract "The purpose of this study was to evaluate the long-term safety and tolerability of paliperidone extended-release (ER) in adolescents with schizophrenia.This was a 2 year open-label, multicenter study in adolescents (12-17 years of age, inclusive) with schizophrenia. Eligible patients were initially treated with 6 mg/day paliperidone ER, and the dose could be adjusted between 1.5 and 12 mg/day based on clinical need. Safety parameters were treatment-emergent adverse events (TEAEs), weight, Tanner staging, blood chemistry (including prolactin, glucose, insulin, and lipid levels), and extrapyramidal symptom (EPS) scales. The main efficacy end-point was change from baseline to endpoint in Positive and Negative Syndrome Scale for Schizophrenia (PANSS) total score.Of 400 enrolled patients (mean age, 15.4 years; boys, 61%), 220 were completers. Median (range) exposure was 604.5 (2-765) days. TEAEs were reported in 85.3% of patients; most frequently reported TEAEs included somnolence, increased weight, headache, insomnia, nasopharyngitis, akathisia, schizophrenia exacerbation, and tremor. No deaths were reported. There were no clinically significant mean changes in growth-adjusted z score for change in weight, height, or body mass index (BMI). Tanner ratings showed normal maturation. Most frequently occurring EPS-related events were related to Parkinsonism (15.5%) and hyperkinesia (13.8%). No cases of tardive dyskinesia were reported. Hyperprolactinemia (based on laboratory values) was noted in 56% of patients and 9.3% of patients had prolactin-related TEAEs. A low percentage of patients (4.3%, n=14) had a shift from normal or impaired fasting glucose to high levels. Mean (SD) decrease (improvement) in PANSS total score from baseline to end-point was -19.1 (21.89). The majority of patients had a ≥20% improvement in PANSS total score (responders) from initial treatment with paliperidone ER. Overall, 41.7% of patients achieved remission during the study.Paliperidone ER was generally tolerable, and exhibited efficacy in the maintenance treatment of schizophrenia in adolescents in this large 2 year study." @default.
• W2174456430 created "2016-06-24" @default.
• W2174456430 creator A5020650497 @default.
• W2174456430 creator A5023527028 @default.
• W2174456430 creator A5043115868 @default.
• W2174456430 creator A5047078649 @default.
• W2174456430 creator A5076376973 @default.
• W2174456430 creator A5086849309 @default.
• W2174456430 date "2015-09-01" @default.
• W2174456430 modified "2023-09-26" @default.
• W2174456430 title "Long-Term Safety of Paliperidone Extended Release in Adolescents with Schizophrenia: An Open-Label, Flexible Dose Study" @default.
• W2174456430 cites W1964074632 @default.
• W2174456430 cites W1973189313 @default.
• W2174456430 cites W1983313230 @default.
• W2174456430 cites W1984390643 @default.
• W2174456430 cites W1985766458 @default.
• W2174456430 cites W1988548270 @default.
• W2174456430 cites W1992181956 @default.
• W2174456430 cites W1998327293 @default.
• W2174456430 cites W2019932021 @default.
• W2174456430 cites W2020724479 @default.
• W2174456430 cites W2040013231 @default.
• W2174456430 cites W2046466188 @default.
• W2174456430 cites W2050493658 @default.
• W2174456430 cites W2053879286 @default.
• W2174456430 cites W2066810529 @default.
• W2174456430 cites W2078872247 @default.
• W2174456430 cites W2097116748 @default.
• W2174456430 cites W2104378301 @default.
• W2174456430 cites W2111838078 @default.
• W2174456430 cites W2113878979 @default.
• W2174456430 cites W2114487561 @default.
• W2174456430 cites W2116738109 @default.
• W2174456430 cites W2127872656 @default.
• W2174456430 cites W2128120675 @default.
• W2174456430 cites W2132327224 @default.
• W2174456430 cites W2135689380 @default.
• W2174456430 cites W2139583609 @default.
• W2174456430 cites W2160412761 @default.
• W2174456430 cites W2169208818 @default.
• W2174456430 doi "https://doi.org/10.1089/cap.2014.0130" @default.
• W2174456430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26218669" @default.
• W2174456430 hasPublicationYear "2015" @default.
• W2174456430 type Work @default.
• W2174456430 sameAs 2174456430 @default.
• W2174456430 citedByCount "15" @default.
• W2174456430 countsByYear W21744564302016 @default.
• W2174456430 countsByYear W21744564302017 @default.
• W2174456430 countsByYear W21744564302018 @default.
• W2174456430 countsByYear W21744564302019 @default.
• W2174456430 countsByYear W21744564302020 @default.
• W2174456430 countsByYear W21744564302021 @default.
• W2174456430 countsByYear W21744564302022 @default.
• W2174456430 countsByYear W21744564302023 @default.
• W2174456430 crossrefType "journal-article" @default.
• W2174456430 hasAuthorship W2174456430A5020650497 @default.
• W2174456430 hasAuthorship W2174456430A5023527028 @default.
• W2174456430 hasAuthorship W2174456430A5043115868 @default.
• W2174456430 hasAuthorship W2174456430A5047078649 @default.
• W2174456430 hasAuthorship W2174456430A5076376973 @default.
• W2174456430 hasAuthorship W2174456430A5086849309 @default.
• W2174456430 hasConcept C118552586 @default.
• W2174456430 hasConcept C126322002 @default.
• W2174456430 hasConcept C15744967 @default.
• W2174456430 hasConcept C197934379 @default.
• W2174456430 hasConcept C2776412080 @default.
• W2174456430 hasConcept C2777393122 @default.
• W2174456430 hasConcept C2778375690 @default.
• W2174456430 hasConcept C2779034229 @default.
• W2174456430 hasConcept C2779727114 @default.
• W2174456430 hasConcept C2780135775 @default.
• W2174456430 hasConcept C2780221984 @default.
• W2174456430 hasConcept C2780494398 @default.
• W2174456430 hasConcept C2780616385 @default.
• W2174456430 hasConcept C71924100 @default.
• W2174456430 hasConceptScore W2174456430C118552586 @default.
• W2174456430 hasConceptScore W2174456430C126322002 @default.
• W2174456430 hasConceptScore W2174456430C15744967 @default.
• W2174456430 hasConceptScore W2174456430C197934379 @default.
• W2174456430 hasConceptScore W2174456430C2776412080 @default.
• W2174456430 hasConceptScore W2174456430C2777393122 @default.
• W2174456430 hasConceptScore W2174456430C2778375690 @default.
• W2174456430 hasConceptScore W2174456430C2779034229 @default.
• W2174456430 hasConceptScore W2174456430C2779727114 @default.
• W2174456430 hasConceptScore W2174456430C2780135775 @default.
• W2174456430 hasConceptScore W2174456430C2780221984 @default.
• W2174456430 hasConceptScore W2174456430C2780494398 @default.
• W2174456430 hasConceptScore W2174456430C2780616385 @default.
• W2174456430 hasConceptScore W2174456430C71924100 @default.
• W2174456430 hasIssue "7" @default.
• W2174456430 hasLocation W21744564301 @default.
• W2174456430 hasLocation W21744564302 @default.
• W2174456430 hasOpenAccess W2174456430 @default.
• W2174456430 hasPrimaryLocation W21744564301 @default.
• W2174456430 hasRelatedWork W1976211188 @default.
• W2174456430 hasRelatedWork W1989320180 @default.
• W2174456430 hasRelatedWork W2033155032 @default.
• W2174456430 hasRelatedWork W2061864344 @default.

• next